FDA puts Cadence pain drug app on hold

The FDA has put Cadence Pharma's application to market its pain and fever therapy on hold. The agency alerted Cadence that it couldn't approve the drug--to be marketed as Ofirmev--until manufacturing problems at a third-party facility were resolved. Cadence emphasized that the FDA did not ask for any new studies. Cadence release | Report